Aiolos Bio Launches with $245M Series A Investment
- gdelacruz57
- Oct 25, 2023
- 1 min read
San Francisco and London, October 24, 2023 (Business Wire) -- Aiolos Bio, Inc. officially launches as a clinical-stage biopharmaceutical company, committed to addressing unmet medical needs in respiratory and inflammatory conditions. The company secures an oversubscribed $245 million in Series A funding.
Read full article here.
コメント